Just about every state is lifting some coronavirus-related restrictions, but it’s unclear how things are really going, considering data on the spread of the virus lags and may not be reliable. Meanwhile, the federal government continues to throw more responsibility for dealing with the pandemic to state and local governments. Margot Sanger-Katz of The New York Times, Kimberly Leonard of Business Insider and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more.
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?
Vaccines and antivirals have long been an afterthought but Johnson & Johnson and other firms are widely publicizing how they might stop COVID 19.
Thousands of researchers worldwide are looking for a treatment that will go beyond what remdesivir can do for COVID patients.
Activists failed to convince state legislators that diseases like measles aren’t serious enough to require vaccination. Now they’re joining with conservatives and other anti-lockdown demonstrators who contend the coronavirus isn’t dangerous enough to justify staying home.
President Donald Trump says the country has seen a peak in new cases, but that doesn’t mean the end of the pandemic, experts say. Buckle in — we could be social distancing into 2022.
These FAQs provide the latest guidance on testing and treatment related to COVID-19 for Medicare beneficiaries, including questions related to out-of-pocket costs, the COVID-19 vaccine, telehealth, extended supplies of medication, skilled nursing facil…
States tried to tighten vaccine requirements last year in the midst of measles outbreaks, but a backlash against a tougher law in Maine put a referendum on the ballot there. Voters weigh in on Super Tuesday.
Health care experts thought the battle was won against heart disease, measles, smoking, STDs and other life-threatening conditions and behaviors. Better think again.
In the past decade, federal and state governments have removed cost and access obstacles, but immunization rates remained flat. That worries public health officials.
